Sanofi-Aventis launched a hostile bid for Genzyme at $69 per share, taking its $18.5 billion offer direct to shareholders after the biotech’s management refused to negotiate.
*For more on this story, read the full Reuters article.
Sanofi-Aventis launched a hostile bid for Genzyme at $69 per share, taking its $18.5 billion offer direct to shareholders after the biotech’s management refused to negotiate.
*For more on this story, read the full Reuters article.
Sign-up for our FREE Daily eNews update to get the latest Orange County news delivered right to your inbox!
One-Year for Only $99